Europe Human Microbiome Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The European human microbiome market is projected to grow significantly, reaching approximately USD 999.66 million by 2031, up from USD 204.79 million in 2023, reflecting a compound annual growth rate (CAGR) of 21.9% from 2023 to 2031.

Executive Summary and Market Analysis

The market is divided into key regions: France, Germany, the UK, and the Rest of Europe. Europe plays a crucial role in the global human microbiome market and is anticipated to experience strong growth during the period from 2023 to 2031. This growth is driven by an increase in research studies focused on the human microbiome and a rise in chronic diseases and disorders. Additionally, the expansion of various research initiatives related to human microbiomes is expected to be a primary factor propelling market growth in Europe.

Market Segmentation Analysis

The Europe human microbiome market can be analyzed through several key segments: type, application, and disease type.

By Type: The market is categorized into products and software/services. In 2023, the product segment dominated the market, which is further divided into probiotics and prebiotics.
By Application: The market is segmented into therapeutics, diagnostics, and research, with therapeutics holding the largest market share in 2023.
By Disease Type: The market is classified into categories such as obesity, diabetes, autoimmune disorders, cancer, gastrointestinal (GIT) issues, and others, with GIT issues leading the market in 2023.

Market Outlook

The growth and dynamics of the human microbiome industry are significantly influenced by investments from major market players. These companies are heavily investing in research and development to create innovative probiotics, diagnostics, and microbiome-based treatments. Such investments foster innovation, leading to the discovery of new strains, mechanisms of action, and therapeutic applications. Clinical trials, which require substantial funding, are essential for validating the safety and efficacy of microbiome-related products.

For instance, Kanvas Biosciences, a leader in microbiome mapping technology, secured USD 12 million in a Pre-Series A funding round in June 2023. This funding will support the advancement of their proprietary platform technology aimed at revolutionizing drug development for microbiome-related diseases. Furthermore, collaborations among companies enhance resource sharing, expertise, and technological advancements, accelerating product development. A notable partnership was formed in July 2023 between Nestle, the largest food and beverage company globally, and APC Microbiome Ireland, a leading research center, focusing on various aspects of the human microbiome to develop new health-enhancing products. Currently, around 120 companies are investing in microbiome analysis, with numerous startups entering the sector. Key investors include Flagship Pioneering, Seventure Partners, and BioGaia, indicating that increased investment from these players is likely to drive market growth.

Country Insights

The European human microbiome market includes countries such as the UK, Germany, France, Italy, Spain, and others. Germany emerged as the largest market in 2023, recognized as a significant hub for biotechnological research in Europe and globally. This is attributed to the presence of major biotechnology firms, advanced research facilities, and substantial funding for research and development. The ongoing R&D activities and favorable government regulations for microbiome therapeutics development in Germany present lucrative opportunities. For example, in 2022, Vagisan ProbioFlora, produced by Dr. Wolff Group, was reclassified and received medicinal product status, positively impacting the broader microbiome-driven pharmaceutical industry.

In March 2023, mbiomics GmbH announced a successful first closing of its Series A financing round, raising EUR 13 million (approximately USD 15 million), led by MIG Capital with participation from High-Tech Grunderfonds, Bayern Kapital, and private investors. Mbiomics utilizes its proprietary high-resolution profiling platform to design effective microbial consortia for precision therapies and improve patient selection and monitoring in clinical trials.

Company Profiles

Key players in the human microbiome market include MaaT Pharma, Ferring Holdings SA, AOBiome Therapeutics Inc, Finch Therapeutics Group Inc, Seres Therapeutics Inc, Merck & Co Inc, Rebiotix, Inc., Yakult Honsha Co., Ltd., IFF Nutrition & Biosciences, and Synthetic Biologics, Inc. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their product offerings and increase market share.

Product Code: TIPRE00003318

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Europe Human Microbiome Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Europe Human Microbiome Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Significant Investments by Key Market Players
- 5.1.2 Government Initiatives
5.2 Market Restraints
- 5.2.1 Challenges During Production of Microbiome
5.3 Market Opportunities
- 5.3.1 Robust Investment in Research and Development
5.4 Future Trends
- 5.4.1 Emergence of Precision Medicine
5.5 Impact of Drivers and Restraints:

6. Human Microbiome Market - Europe Analysis

6.1 Europe Human Microbiome Market Revenue (US$ Million), 2021-2031
6.2 Europe Human Microbiome Market Forecast Analysis

7. Europe Human Microbiome Market Analysis - by Type

7.1 Product
- 7.1.1 Overview
- 7.1.2 Product: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Software and Services
- 7.2.1 Overview
- 7.2.2 Software and Services: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Human Microbiome Market Analysis - by Application

8.1 Therapeutics
- 8.1.1 Overview
- 8.1.2 Therapeutics: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Diagnostics
- 8.2.1 Overview
- 8.2.2 Diagnostics: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Research
- 8.3.1 Overview
- 8.3.2 Research: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Human Microbiome Market Analysis - by Disease Type

9.1 Obesity
- 9.1.1 Overview
- 9.1.2 Obesity: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Diabetes
- 9.2.1 Overview
- 9.2.2 Diabetes: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Autoimmune Disorder
- 9.3.1 Overview
- 9.3.2 Autoimmune Disorder: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.4 Cancer
- 9.4.1 Overview
- 9.4.2 Cancer: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.5 GIT
- 9.5.1 Overview
- 9.5.2 GIT: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Europe Human Microbiome Market - Country Analysis

10.1 Europe
- 10.1.1 Europe Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.1 Europe Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.2 United Kingdom: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.2.1 United Kingdom: Europe Human Microbiome Market Share - by Type
    - 10.1.1.2.2 United Kingdom: Europe Human Microbiome Market Share - by Product
    - 10.1.1.2.3 United Kingdom: Europe Human Microbiome Market Share - by Application
    - 10.1.1.2.4 United Kingdom: Europe Human Microbiome Market Share - by Disease Type
  - 10.1.1.3 Germany: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.3.1 Germany: Europe Human Microbiome Market Share - by Type
    - 10.1.1.3.2 Germany: Europe Human Microbiome Market Share - by Product
    - 10.1.1.3.3 Germany: Europe Human Microbiome Market Share - by Application
    - 10.1.1.3.4 Germany: Europe Human Microbiome Market Share - by Disease Type
  - 10.1.1.4 France: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.4.1 France: Europe Human Microbiome Market Share - by Type
    - 10.1.1.4.2 France: Europe Human Microbiome Market Share - by Product
    - 10.1.1.4.3 France: Europe Human Microbiome Market Share - by Application
    - 10.1.1.4.4 France: Europe Human Microbiome Market Share - by Disease Type
  - 10.1.1.5 Italy: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.5.1 Italy: Europe Human Microbiome Market Share - by Type
    - 10.1.1.5.2 Italy: Europe Human Microbiome Market Share - by Product
    - 10.1.1.5.3 Italy: Europe Human Microbiome Market Share - by Application
    - 10.1.1.5.4 Italy: Europe Human Microbiome Market Share - by Disease Type
  - 10.1.1.6 Spain: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.6.1 Spain: Europe Human Microbiome Market Share - by Type
    - 10.1.1.6.2 Spain: Europe Human Microbiome Market Share - by Product
    - 10.1.1.6.3 Spain: Europe Human Microbiome Market Share - by Application
    - 10.1.1.6.4 Spain: Europe Human Microbiome Market Share - by Disease Type
  - 10.1.1.7 Rest of Europe: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.7.1 Rest of Europe: Europe Human Microbiome Market Share - by Type
    - 10.1.1.7.2 Rest of Europe: Europe Human Microbiome Market Share - by Product
    - 10.1.1.7.3 Rest of Europe: Europe Human Microbiome Market Share - by Application
    - 10.1.1.7.4 Rest of Europe: Europe Human Microbiome Market Share - by Disease Type

11. Industry Landscape

11.1 Overview
11.2 Growth Strategies in the Human Microbiome Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 MaaT Pharma
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Ferring Holdings SA
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 AOBiome Therapeutics Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Finch Therapeutics Group Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Financial Overview
- 12.4.4 SWOT Analysis
- 12.4.5 Key Developments
12.5 Seres Therapeutics Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Merck & Co Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Yakult Honsha Co., Ltd.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Rebiotix, Inc.
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 IFF Nutrition & Biosciences
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Synthetic Biologics, Inc.
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About Us
13.2 List of Abbreviations